| This week's sponsor is Premier Research. | | | >From Lab to Bedside: The Latest Rare Oncology Drug Research
Study of rare cancers demands immersion in dual indications where strategies often don't mesh. Attend our Feb. 28 webinar for fresh insights on speeding development of new drugs. Register now. Premier Research. It's what we do. Best. |
Top Stories Thursday, February 9, 2017 A phase 3 clinical trial of Acorda Therapeutics’ inhaled formulation of levodopa has met its primary endpoint. The study linked the high dose of CVT-301 to a statistically significant improvement in scores on a Parkinson’s disease motor impairment scale, setting Acorda up to file for approval in the second quarter. Thursday, February 9, 2017 Denmark has formally joined the list of countries competing to host the European Medicines Agency (EMA) after Brexit. And the campaign has already enlisted high-profile support, with local success story Novo Nordisk talking up Copenhagen and its ex-CEO Lars Rebien Sorensen signing up as special envoy for the bid. Thursday, February 9, 2017 Jeremy Levin’s Ovid Therapeutics and NeuroPointDX have signed a new collaboration that sees the pair seek out new biomarkers of the rare disorder Angelman syndrome. Thursday, February 9, 2017 Researchers from Epinomics have penned a collaboration with the Parker Institute for Cancer Immunotherapy to use biomarkers from the company to help boost outcomes and lower adverse events in immunotherapy trials. Wednesday, February 8, 2017 MRSA has outfoxed every beta-lactam antibiotic, including methicillin, penicillin and amoxicillin. But scientists at Florida Atlantic University have found that a compound extracted from a marine sponge had an antibacterial effect against MRSA, highlighting a potential new angle to treat the drug-resistant bacterium. Wednesday, February 8, 2017 Regeneron and Sanofi won’t have to pull Praluent off the market, at least not yet. A U.S. appeals court on Wednesday decided to let the PCSK9 cholesterol drug remain on pharmacy shelves while it sorts out an appeal in a patent fight with Amgen, which makes a rival drug. | | | Oxford BioTherapeutics has boosted its board with the appointment of two biotech vets. Statement Ignyta has posted updated early-stage data for its candidate entrectinib in cancers with TRK, ROS1 or ALK fusions in Cancer Discovery. Release Armetheon says it has agreed with the FDA to conduct a 1,000-patient phase 3 test before filing an NDA for its anticoagulant tecarfarin. Statement | |
|
Resources Sponsored By: Veeva Learn over a dozen best practices for deploying a global content system. Read Whitepaper. Sponsored By: Veeva Gartner provides insightful research on preparing for IDMP compliance. Read Whitepaper. Sponsored By: Veeva Learn How to Create a Unified RIM Environment for IDMP. Find out. Sponsored By: Veeva The largest survey of TMF owners reveals drivers and trends in improving inspection readiness and shortening trial time. Sponsored By: Salesforce Learn how the healthcare and life science industry is using agile application development to drive innovation and accelerate their business with the Salesforce Platform. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA PEGS: The Essential Protein Engineering Summit May 1-5, 2017 | Boston, MA BIO CEO & Investor Conference February 13 – 14, 2017 | The Waldorf Astoria, New York, NY | 